Brain Radiotherapy Plus Continued Systemic Therapy Improves Survival in Brain-Only Progressive Extensive-Stage Small Cell Lung Cancer

Clinical Summary: 

• Design/Population: This multicenter cohort study evaluated second-line treatment strategies in patients with extensive-stage small cell lung cancer who developed brain-only progression after first-line therapy.
• Key Outcomes: Continuing the original systemic therapy combined with brain radiotherapy significantly improved overall survival and second-line progression-free survival compared with switching systemic therapy. The greatest benefit was observed in patients with prior immunotherapy exposure and longer initial progression-free survival.
• Clinical Relevance: These findings support a site-directed treatment approach for brain-only progression in extensive-stage small cell lung cancer, suggesting that maintaining an effective systemic regimen while controlling intracranial disease with radiotherapy may improve clinical outcomes.

Results from a multicenter cohort study demonstrated that continuing the original systemic therapy plus brain radiotherapy improved survival in patients with extensive-stage small cell lung cancer (ES-SCLC) who developed brain-only progression after first-line treatment, supporting a site-directed treatment strategy in this setting.

“For brain-only progression, there is no consensus on whether to continue the original systemic therapy, substitution therapy, or integrate brain radiotherapy,” stated Shuangqing Lu, MD, Shandong Cancer Hospital and Institute, Shandong Province, China, and coauthors. “Given uncertainties around immunotherapy's pharmacologic penetration and activity in the CNS and the still-emerging evidence for radio-immunotherapy synergy in SCLC formulating site-directed, progression pattern–informed second-line strategies is especially important.”

In this study, researchers identified 203 patients with ES-SCLC who developed brain-only progression after first-line platinum-etoposide chemotherapy with or without immunotherapy. Patients either continued their original systemic therapy with brain radiotherapy (n = 71), switched to a new systemic therapy with brain radiotherapy (n = 64), or switched to a new systemic therapy alone (n = 68). The primary end point was overall survival (OS) from initiation of second-line treatment. A key secondary end point was second-line progression-free survival (PFS).

In the inverse probability of treatment weighting analysis, continuing the original systemic therapy with brain radiotherapy resulted in the longest median OS at 14.7 months compared with 10.2 months for patients who switched systemic therapy alone (hazard ratio [HR], 1.68; P = .028) and 9.8 months for those who switched systemic therapy plus brain radiotherapy (HR, 1.67; P = .023). Median second-line PFS was also significantly longer with continuation of the original systemic therapy plus brain radiotherapy than with systemic therapy alone (8 vs 4 months; P = .024). Multivariable analysis confirmed continuation of the original systemic therapy plus brain radiotherapy as an independent predictor of improved survival.

The survival advantage was greatest among patients who had received prior immunotherapy and among those whose initial PFS was at least 7.5 months. In contrast, no significant survival differences were observed according to the type of brain radiotherapy administered, including whole-brain radiotherapy and stereotactic radiosurgery.

“For ES-SCLC patients with [brain-only progression], continuing the original systemic regimen plus [brain radiotherapy] yields superior survival compared with switching systemic therapy,” concluded Dr Lu et al.

“The results of this study suggest that the pattern of recurrence may influence the optimal salvage therapy, supporting continuation of the original systemic therapy and adding radiation therapy to the brain for [brain-only progression],” added Journal of Clinical Oncology associate editor Caroline Chung, MD, MD Anderson Cancer Center, Houston, Texas. 

Source: 

Lu S, Jia J, Ren K, et al. Multicenter cohort study of original or substitute systemic therapy with or without brain radiotherapy for extensive-stage small cell lung cancer with brain-only progression after first-line treatment. J Clin Oncol. Published online: May 14, 2026. doi: 10.1200/JCO-25-02536